Abstract
Inositol hexaphosphate (IP6, InsP6) is a polyphosphorylated carbohydrate with diverse signaling properties. IP6 is plentiful in organisms as diverse as yeast, actinobacteria, mammals and plants. In the plant kingdom, IP6 accumulates during seed development; during germination it is broken down into lower inositol phosphates and micronutrients to maintain seedling. IP6 is the most abundant of the intracellular inositol phosphates in eukaryotes. In mammals IP6 maintains homeostasis, stores phosphate and acts as a strong anti-oxidant and neurotransmitter. IP6’s rapid phosphate turnover properties justify its critical role in cellular pathways involved in signal transduction, control of cell proliferation and differentiation, RNA export, DNA repair, energy transduction and ATP regeneration. The health benefits of IP6 have been demonstrated to lower serum cholesterol level, normalize pathological platelet activity and prevent pathological calcification and kidney stone formation. It is also a potent antioxidant and immunity enhancer. However, it is the field of cancer prevention and therapy that may be the biggest career for IP6. In this review we present updated knowledge on signaling events caused by this fascinating, ubiquitous molecule that has numerous functions.
Keywords: IP6, inositol, phytate, polyphosphates, signal transduction, nutraceuticals, actinobacteria, myo-isoform, pentakisphosphate, Myxobacteria
Current Signal Transduction Therapy
Title:IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Volume: 7 Issue: 3
Author(s): Abul Kalam Shamsuddin and Sanchita Bose
Affiliation:
Keywords: IP6, inositol, phytate, polyphosphates, signal transduction, nutraceuticals, actinobacteria, myo-isoform, pentakisphosphate, Myxobacteria
Abstract: Inositol hexaphosphate (IP6, InsP6) is a polyphosphorylated carbohydrate with diverse signaling properties. IP6 is plentiful in organisms as diverse as yeast, actinobacteria, mammals and plants. In the plant kingdom, IP6 accumulates during seed development; during germination it is broken down into lower inositol phosphates and micronutrients to maintain seedling. IP6 is the most abundant of the intracellular inositol phosphates in eukaryotes. In mammals IP6 maintains homeostasis, stores phosphate and acts as a strong anti-oxidant and neurotransmitter. IP6’s rapid phosphate turnover properties justify its critical role in cellular pathways involved in signal transduction, control of cell proliferation and differentiation, RNA export, DNA repair, energy transduction and ATP regeneration. The health benefits of IP6 have been demonstrated to lower serum cholesterol level, normalize pathological platelet activity and prevent pathological calcification and kidney stone formation. It is also a potent antioxidant and immunity enhancer. However, it is the field of cancer prevention and therapy that may be the biggest career for IP6. In this review we present updated knowledge on signaling events caused by this fascinating, ubiquitous molecule that has numerous functions.
Export Options
About this article
Cite this article as:
Kalam Shamsuddin Abul and Bose Sanchita, IP6 (Inositol Hexaphosphate) as a Signaling Molecule, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481628
DOI https://dx.doi.org/10.2174/157436212802481628 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pomelo Peel Volatile Oil Alleviates Neuroinflammation on Focal Cerebral Ischemia Reperfusion Injury Rats via Inhibiting TLR4/NF-κB Signaling Pathway
Current Pharmaceutical Biotechnology Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Oxidative Stress: Apoptosis in Neuronal Injury
Current Alzheimer Research Potential of Sulphur-containing Amino Acids in the Prevention of Catecholamine-induced Arrhythmias
Current Medicinal Chemistry Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Withdrawal Notice: Therapeutic Effect of Prdx1 on NAFLD Mice May be Related to the Activation of Nrf-2/HO-1 Pathway
Current Pharmaceutical Design The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design